Genetically Engineered Mouse Models in Cancer Drug Development
Abstract
Keywords
Full Text:
PDFReferences
Society for Clinical Trials Board of Directors, The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients, Clin. Trials 3 (2006) 154–157.
M. Suggitt, M.C. Bibby, 50 years of preclinical anticancer drug screening: empirical to target-driven approaches, Clin. Cancer Res. 11 (2005) 971–981.
E.A. Sausville, A.M. Burger, Contributions of human tumor xenografts to anticancer drug development, Cancer Res. 66 (2006) 3351–3354.
T. Van Dyke, T. Jacks, Cancer modeling in the modern era: progress and challenges, Cell. 108 (2002) 135–144.
A. Leder, P.K. Pattengale, A. Kuo, T.A. Stewart, P. Leder, Con- sequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development, Cell 45 (1986) 485–495
C.T. Guy, R.D. Cardiff, W.J. Muller, Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease, Mol. Cell. Biol. 12 (1992) 954–961.
J.E. Maglione, E.T. McGoldrick, L.J. Young, R. Namba, J.P. Gregg, L. Liu, D. Moghanaki, L.G. Ellies, A.D. Borowsky, R.D. Cardiff, C.L. MacLeod, Polyomavirus middle T-induced mammary intra epithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes, Mol. Cancer Ther. 3 (2004) 941–953.
H.H. Fiebig, A.M. Burger, Human tumor xenografts and explants, in: B.A. Teicher (Ed.), Tumor Models in Cancer Research, Humana Press Inc., 2002, pp. 113–137.
S. Huang, Y. Li, Y. Chen, K. Podsypanina, M. Chamorro, A.B. Olshen, K.V. Desai, A. Tann, D. Petersen, J.E. Green, H.E. Varmus, Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice, Genome Biol. 6 (2005) R84.
Refbacks
- There are currently no refbacks.